EPTIFIBATIDE

Eptifibatide Adverse Events Reported to the FDA Over Time

How are Eptifibatide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Eptifibatide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Eptifibatide is flagged as the suspect drug causing the adverse event.

Most Common Eptifibatide Adverse Events Reported to the FDA

What are the most common Eptifibatide adverse events reported to the FDA?

Myocardial Infarction	52 (4.75%)
Thrombocytopenia	51 (4.66%)
Hypotension	26 (2.38%)
Cardiogenic Shock	18 (1.65%)
Epistaxis	18 (1.65%)
Anaemia	16 (1.46%)
Haemorrhage	16 (1.46%)
Post Procedural Complication	16 (1.46%)
Haemoglobin Decreased	15 (1.37%)
Acute Myocardial Infarction	13 (1.19%)
Haematoma	13 (1.19%)
	Show More
Cardiac Arrest	12 (1.1%)
Haematocrit Decreased	12 (1.1%)
Haematuria	12 (1.1%)
Platelet Count Decreased	12 (1.1%)
Pulmonary Alveolar Haemorrhage	12 (1.1%)
Chest Pain	11 (1.01%)
Dizziness	11 (1.01%)
Gastrointestinal Haemorrhage	11 (1.01%)
Renal Failure Acute	11 (1.01%)
Coronary Artery Disease	10 (.91%)
Bradycardia	9 (.82%)
Cerebral Haemorrhage	9 (.82%)
Dyspnoea	9 (.82%)
Haemoptysis	9 (.82%)
Heparin-induced Thrombocytopenia	9 (.82%)
Multi-organ Failure	9 (.82%)
Respiratory Failure	9 (.82%)
Asthenia	8 (.73%)
Pulmonary Congestion	8 (.73%)
Pulmonary Oedema	8 (.73%)
Thrombosis In Device	8 (.73%)
Arrhythmia Supraventricular	7 (.64%)
Cardio-respiratory Arrest	7 (.64%)
Gastric Haemorrhage	7 (.64%)
Mitral Valve Incompetence	7 (.64%)
Renal Failure	7 (.64%)
Vascular Pseudoaneurysm	7 (.64%)
Anaphylactic Shock	6 (.55%)
Cardiac Failure	6 (.55%)
Coronary Artery Thrombosis	6 (.55%)
Dialysis	6 (.55%)
Drug Ineffective	6 (.55%)
Haematemesis	6 (.55%)
Haemorrhage Intracranial	6 (.55%)
Leukocytosis	6 (.55%)
Nausea	6 (.55%)
Post Procedural Haemorrhage	6 (.55%)
Pyrexia	6 (.55%)
Vomiting	6 (.55%)
Chest Discomfort	5 (.46%)
Cough	5 (.46%)
Death	5 (.46%)
Depressed Level Of Consciousness	5 (.46%)
Dysphagia	5 (.46%)
Gastric Ulcer	5 (.46%)
Gastritis Erosive	5 (.46%)
Hypoxia	5 (.46%)
Pericardial Effusion	5 (.46%)
Rectal Haemorrhage	5 (.46%)
Respiratory Distress	5 (.46%)
Retroperitoneal Haemorrhage	5 (.46%)
Tremor	5 (.46%)
Troponin Increased	5 (.46%)
Agitation	4 (.37%)
Brain Stem Infarction	4 (.37%)
Cardiac Procedure Complication	4 (.37%)
Cardiomyopathy	4 (.37%)
Cardiovascular Disorder	4 (.37%)
Confusional State	4 (.37%)
Coronary Artery Occlusion	4 (.37%)
Duodenal Ulcer	4 (.37%)
Groin Pain	4 (.37%)
Hypersensitivity	4 (.37%)
Lower Gastrointestinal Haemorrhage	4 (.37%)
Procedural Complication	4 (.37%)
Shock	4 (.37%)
Ventricular Fibrillation	4 (.37%)
Ventricular Tachycardia	4 (.37%)
Wound Secretion	4 (.37%)
Anaesthetic Complication Neurologic...	3 (.27%)
Angioedema	3 (.27%)
Back Pain	3 (.27%)
Blood Creatine Phosphokinase Mb Inc...	3 (.27%)
Body Temperature Increased	3 (.27%)
Cardiac Enzymes Increased	3 (.27%)
Cardiac Tamponade	3 (.27%)
Catheter Related Complication	3 (.27%)
Catheter Site Haematoma	3 (.27%)
Catheter Thrombosis	3 (.27%)
Chills	3 (.27%)
Condition Aggravated	3 (.27%)
Faeces Discoloured	3 (.27%)
Fatigue	3 (.27%)
Infusion Related Reaction	3 (.27%)
Malaise	3 (.27%)
Melaena	3 (.27%)
Myocardial Ischaemia	3 (.27%)
No Therapeutic Response	3 (.27%)
Oxygen Saturation Decreased	3 (.27%)
Pleural Effusion	3 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Eptifibatide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Eptifibatide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Eptifibatide

What are the most common Eptifibatide adverse events reported to the FDA?

Coronary Artery	97 (8.87%)
Platelet	60 (5.48%)
Procedural And Device Related Injur...	59 (5.39%)
Cardiac Arrhythmias	54 (4.94%)
Respiratory	54 (4.94%)
Hematology Investigations	47 (4.3%)
Gastrointestinal Hemorrhages	40 (3.66%)
Lower Respiratory Tract Disorders	37 (3.38%)
Decreased And Nonspecific Blood Pre...	33 (3.02%)
Central Nervous System Vascular	32 (2.93%)
Vascular Hemorrhagic	29 (2.65%)
	Show More
Neurological	28 (2.56%)
Heart Failures	27 (2.47%)
Gastrointestinal Signs	25 (2.29%)
Administration Site Reactions	20 (1.83%)
Upper Respiratory Tract Disorders	20 (1.83%)
Anemias Nonhemolytic And Marrow Dep...	19 (1.74%)
Renal Disorders	19 (1.74%)
Myocardial	17 (1.55%)
Gastrointestinal Ulceration And Per...	16 (1.46%)
Allergic Conditions	14 (1.28%)
Cardiac And Vascular Investigations	14 (1.28%)
Urinary Tract Signs	13 (1.19%)
Enzyme	12 (1.1%)
Therapeutic And Nontherapeutic Effe...	12 (1.1%)
Hematological And Lymphoid Tissue T...	11 (1.01%)
Injuries	11 (1.01%)
Musculoskeletal And Connective Tiss...	9 (.82%)
Pericardial	9 (.82%)
Cardiac Disorder Signs	8 (.73%)
Vascular	8 (.73%)
Cardiac Valve	7 (.64%)
Deliria	7 (.64%)
Epidermal And Dermal Conditions	7 (.64%)
Infections - Pathogen Unspecified	7 (.64%)
Peritoneal And Retroperitoneal Cond...	7 (.64%)
White Blood Cell	7 (.64%)
Angiedema And Urticaria	6 (.55%)
Body Temperature Conditions	6 (.55%)
Fatal Outcomes	6 (.55%)
Medication Errors	6 (.55%)
Movement Disorders	6 (.55%)
Immunology And Allergy	5 (.46%)
Joint	5 (.46%)
Pleural	5 (.46%)
Anxiety Disorders	4 (.37%)
Coagulopathies And Bleeding Diathes...	4 (.37%)
Physical Examination Topics	4 (.37%)
Respiratory And Pulmonary Investiga...	4 (.37%)
Arteriosclerosis, Stenosis, Vascula...	3 (.27%)
Bacterial Infectious	3 (.27%)
Metabolic, Nutritional And Blood Ga...	3 (.27%)
Retina, Choroid And Vitreous Hemorr...	3 (.27%)
Skin Vascular Abnormalities	3 (.27%)
Aneurysms And Artery Dissections	2 (.18%)
Bone Disorders	2 (.18%)
Changes In Physical Activity	2 (.18%)
Dental And Gingival Conditions	2 (.18%)
Depressed Mood Disorders	2 (.18%)
Gastrointestinal Motility And Defec...	2 (.18%)
Lifestyle Issues	2 (.18%)
Mental Impairment	2 (.18%)
Mood Disorders	2 (.18%)
Muscle	2 (.18%)
Ocular Neuromuscular	2 (.18%)
Oral Soft Tissue Conditions	2 (.18%)
Psychiatric	2 (.18%)
Pulmonary Vascular	2 (.18%)
Renal And Urinary Tract Investigati...	2 (.18%)
Skin Appendage Conditions	2 (.18%)
Vascular Hypertensive	2 (.18%)
Acid-base	1 (.09%)
Aural	1 (.09%)
Bone And Joint Injuries	1 (.09%)
Cardiac And Vascular Disorders Cong...	1 (.09%)
Cardiac Therapeutic Procedures	1 (.09%)
Chemical Injury And Poisoning	1 (.09%)
Connective Tissue Disorders	1 (.09%)
Cranial Nerve Disorders	1 (.09%)
Electrolyte And Fluid Balance Condi...	1 (.09%)
Embolism And Thrombosis	1 (.09%)
Eye	1 (.09%)
Fetal Complications	1 (.09%)
Gastrointestinal Conditions	1 (.09%)
Gastrointestinal Inflammatory Condi...	1 (.09%)
Gastrointestinal Vascular Condition...	1 (.09%)
Headaches	1 (.09%)
Hepatic And Hepatobiliary	1 (.09%)
Hepatobiliary	1 (.09%)
Metabolism	1 (.09%)
Musculoskeletal And Connective Tiss...	1 (.09%)
Neurological Disorders Of The Eye	1 (.09%)
Neuromuscular	1 (.09%)
Obstetric And Gynecological Therape...	1 (.09%)
Personality Disorders	1 (.09%)
Purine And Pyrimidine Metabolism	1 (.09%)
Respiratory Tract Therapeutic Proce...	1 (.09%)
Sleep Disorders	1 (.09%)
Spinal Cord And Nerve Root	1 (.09%)
Spleen, Lymphatic And Reticulendoth...	1 (.09%)
Tongue Conditions	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Eptifibatide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Eptifibatide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.